474 related articles for article (PubMed ID: 14517845)
1. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
2. Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma.
Karjalainen JM; Kellokoski JK; Mannermaa AJ; Kujala HE; Moisio KI; Mitchell PJ; Eskelinen MJ; Alhava EM; Kosma VM
Br J Cancer; 2000 Jun; 82(12):2015-21. PubMed ID: 10864211
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of melanoma metastasis.
Bar-Eli M
J Cell Physiol; 1997 Nov; 173(2):275-8. PubMed ID: 9365536
[TBL] [Abstract][Full Text] [Related]
4. TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin.
Poetsch M; Dittberner T; Cowell JK; Woenckhaus C
Oncogene; 2000 Nov; 19(50):5817-20. PubMed ID: 11126369
[TBL] [Abstract][Full Text] [Related]
5. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
6. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
7. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
8. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
9. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
10. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer.
Gee JM; Robertson JF; Ellis IO; Nicholson RI; Hurst HC
J Pathol; 1999 Dec; 189(4):514-20. PubMed ID: 10629551
[TBL] [Abstract][Full Text] [Related]
12. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of cerbB3 in naevi and malignant melanomas.
Korabiowska M; Mirecka J; Brinck U; Hoefer K; Marx D; Schauer A
Anticancer Res; 1996; 16(1):471-4. PubMed ID: 8615656
[TBL] [Abstract][Full Text] [Related]
14. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo.
Gershenwald JE; Sumner W; Calderone T; Wang Z; Huang S; Bar-Eli M
Oncogene; 2001 Jun; 20(26):3363-75. PubMed ID: 11423987
[TBL] [Abstract][Full Text] [Related]
15. Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36.
Poetsch M; Dittberner T; Woenckhaus C
Oncogene; 2002 May; 21(19):3038-42. PubMed ID: 12082534
[TBL] [Abstract][Full Text] [Related]
16. Expression of neurotrophins and their receptors in pigment cell lesions of the skin.
Innominato PF; Libbrecht L; van den Oord JJ
J Pathol; 2001 May; 194(1):95-100. PubMed ID: 11329147
[TBL] [Abstract][Full Text] [Related]
17. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
18. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma.
Biermann K; Göke F; Nettersheim D; Eckert D; Zhou H; Kahl P; Gashaw I; Schorle H; Büttner R
J Pathol; 2007 Nov; 213(3):311-8. PubMed ID: 17768701
[TBL] [Abstract][Full Text] [Related]
19. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.
Albino AP; Nanus DM; Mentle IR; Cordon-Cardo C; McNutt NS; Bressler J; Andreeff M
Oncogene; 1989 Nov; 4(11):1363-74. PubMed ID: 2682463
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression.
Gorski DH; Leal AD; Goydos JS
J Am Coll Surg; 2003 Sep; 197(3):408-18. PubMed ID: 12946796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
